UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 266

Sortiert nach

Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2065-2072

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2505-2512

2006

Link zum Volltext

Verfügbarkeit prüfen

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

Annals of surgical oncology, 2006-08, Vol.13 (8), p.1035-1046

2006

Link zum Volltext

Verfügbarkeit prüfen

Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

Journal of clinical oncology, 2004-07, Vol.22 (13), p.2610-2616

2004

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

BMC cancer, 2010-07, Vol.10 (1), p.368-368, Article 368

2010

Link zum Volltext

Verfügbarkeit prüfen

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity

Cancer research (Chicago, Ill.), 2004-03, Vol.64 (6), p.2030-2038

2004

Link zum Volltext

Verfügbarkeit prüfen

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

Oncogene, 2003-01, Vol.22 (3), p.319-329

2003

Link zum Volltext

Verfügbarkeit prüfen

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

Journal of clinical oncology, 2008-07, Vol.26 (21), p.3487-3495

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer

Journal of clinical oncology, 2006-03, Vol.24 (7), p.1145-1151

2006

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

The oncologist (Dayton, Ohio), 2017-12, Vol.22 (12), p.1427-e129

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer

Cancer, 2008-10, Vol.113 (8), p.2046-2052

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer

Investigational new drugs, 2018-10, Vol.36 (5), p.895-902

2018

Link zum Volltext

Verfügbarkeit prüfen

Molecular targeting therapy for pancreatic cancer

Cancer chemotherapy and pharmacology, 2004-09, Vol.54, p.S69-S77

XIONG, Henry Q

2004

Link zum Volltext

Verfügbarkeit prüfen

Aggresome disruption : A novel strategy to enhance bortezomib- induced apoptosis in pancreatic cancer cells

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3773-3781

2006

Link zum Volltext

Verfügbarkeit prüfen

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

Seminars in oncology, 2002-10, Vol.29 (5), p.31-37

2002

Link zum Volltext

Verfügbarkeit prüfen

Yttrium 90 Resin Microspheres for the Treatment of Unresectable Colorectal Hepatic Metastases after Failure of Multiple Chemotherapy Regimens: Preliminary Results

Journal of vascular and interventional radiology, 2005-07, Vol.16 (7), p.937-945

2005

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation

Journal of pain and symptom management, 2007-09, Vol.34 (3), p.244-252

2007

Link zum Volltext

Verfügbarkeit prüfen

NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells

International journal of cancer, 2004-01, Vol.108 (2), p.181-188

2004

Link zum Volltext

Verfügbarkeit prüfen

Cytotoxic Chemotherapy for Pancreatic Cancer : Advances to Date and Future Directions

Drugs (New York, N.Y.), 2006-01, Vol.66 (8), p.1059-1072

2006

Link zum Volltext

Verfügbarkeit prüfen

Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells

Cancer biology & therapy, 2005-11, Vol.4 (11), p.1263-1269

2005

Link zum Volltext

Verfügbarkeit prüfen

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3802-3812

2006

Link zum Volltext

Verfügbarkeit prüfen

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

The Lancet (British edition), 2023-09, Vol.402 (10408), p.1133-1146

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

Investigational new drugs, 2004-11, Vol.22 (4), p.459-466

2004

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

Clinical cancer research, 2005-01, Vol.11 (2), p.678-689

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 266

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(241)
Mit Volltextzugriff
(245)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(182)
Life Sciences & Biomedicine
(98)
Humans
(97)
Male
(53)
Technology
(52)
Female
(47)
Physical Sciences
(46)
Oncology
(38)
Animals
(36)
Middle Aged
(36)
Adult
(33)
Aged
(32)
Biological And Medical Sciences
(31)
Science & Technology - Other Topics
(29)
Medical Sciences
(26)
Physics
(26)
Chemistry
(25)
Materials Science
(24)
Tumors
(24)
Engineering
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer

Molecular targeting therapy for pancreatic cancer

Aggresome disruption : A novel strategy to enhance bortezomib- induced apoptosis in pancreatic cancer cells

Epidermal growth factor receptor-targeted therapy for pancreatic cancer

Yttrium 90 Resin Microspheres for the Treatment of Unresectable Colorectal Hepatic Metastases after Failure of Multiple Chemotherapy Regimens: Preliminary Results

Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation

NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells

Cytotoxic Chemotherapy for Pancreatic Cancer : Advances to Date and Future Directions

Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Suchergebnisse filtern